Involvement of central α1- and α2-adrenoceptors on cardiovascular responses to moxonidine

European Journal of Pharmacology

Volumn 563, Issue 1-3, 2007, Pages 164-171

  Moreira, Thiago S ^a   Takakura, Ana C ^a   Menani, José V ^b   Colombari, Eduardo ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

1 and 2 adrenoceptors; Anti hypertensive; Arterial pressure; Hypotension; Sympathetic activity; Vascular resistance

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CHLORALOSE; IMIDAZOLE; MOXONIDINE; PRAZOSIN; URETHAN; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BRADYCARDIA; BRAIN STEM; BRAIN VENTRICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG MECHANISM; FOREBRAIN; HEART BEAT; HEART RATE; HYPOTENSION; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION; ANIMAL; BLOOD PRESSURE; BRAIN; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; KIDNEY CIRCULATION; METABOLISM; SPLANCHNIC BLOOD FLOW; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN; BRAIN STEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; IMIDAZOLES; INJECTIONS, INTRAVENTRICULAR; MALE; PRAZOSIN; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE; YOHIMBINE;

EID: 34247155806     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.02.002     Document Type: Article

References (40)

1. Allen A.M., and Guyenet P.G. Alpha 2-adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla. Am. J. Physiol. 265 (1993) R1065-R1075
2. Andrade C.A., Barbosa S.P., De Luca Jr. L.A., and Menani J.V. Activation of alpha2-adrenergic receptors into the lateral parabrachial nucleus enhances NaCl intake in rats. Neuroscience 129 (2004) 25-34
3. Andrade C.A., De Luca Jr. L.A., Colombari D.S., and Menani J.V. Alpha2-adrenergic activation in the lateral parabrachial nucleus induces NaCl intake under conditions of systemic hyperosmolarity. Neuroscience 142 (2006) 21-28
4. Armah B.I., Hofferber E., and Stenzel W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung 38 (1988) 1426-1434
5. Badoer E., Head G.A., and Korner P.I. Effects of intracisternal and intravenous alpha-methyldopa and clonidine on haemodynamics and baroreceptor-heart rate reflex properties in conscious rabbits. J. Cardiovasc. Pharmacol. 5 (1983) 760-767
6. Barman S.M., and Gebber G.L. Basis for the naturally occurring activity of rostral ventrolateral medullary sympathoexcitatory neurons. Prog. Brain Res. 81 (1989) 117-129
7. Bousquet P., Feldman J., and Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230 (1984) 232-236
8. de Oliveira L.B., De Luca Jr. L.A., and Menani J.V. Moxonidine and central alpha2 adrenergic receptors in sodium intake. Brain Res. 993 (2003) 177-182
9. El-Ayoubi R., Menaouar A., Gutkowska J., and Mukaddam-Daher S. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. Br. J. Pharmacol. 145 (2005) 50-56
10. Ernsberger P., and Haxhiu M.A. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am. J. Physiol. 273 (1997) R1572-R1579
11. Ernsberger P., Elliot H.L., Weiman H.J., Raap A., Haxhiu M.A., Hofferber E., Low-Kroger A., Reid J.L., and Mest H.J. Moxonidine: a second-generation central antihypertensive agent. Cardiovasc. Drug Rev. 11 (1993) 411-431
12. Ernsberger P., Haxhiu M.A., Graff L.M., Collins L.A., Dreshaj I., Grove D.L., Graves M.E., Schafer S.G., and Christen M.O. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc. Drugs Ther. 8 Suppl. 1 (1994) 27-41
13. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J. Hypertens. 15 (1997) S9-S23
14. Feldman J., Greney H., Monassier L., Vonthron C., Bruban V., Dontenwill M., and Bousquet P. Does a second generation of centrally acting antihypertensive drugs really exist?. J. Auton. Nerv. Syst. 72 (1998) 94-97
15. George O.K., Gonzalez Jr. R.R., and Edwards L.P. Moxonidine, an antihypertensive agent, is permissive to alpha1-adrenergic receptor pathway in the rat-tail artery. J. Cardiovasc. Pharmacol. 43 (2004) 306-311
16. Gomez R.E., Ernsberger P., Feinland G., and Reis D.J. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur. J. Pharmacol. 195 (1991) 181-191
17. Guyenet P.G. Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites?. Am. J. Physiol. 273 (1997) R1580-R1584
18. Guyenet P.G. The sympathetic control of blood pressure. Nat. Rev., Neurosci. 7 (2006) 335-346
19. Guyenet P.G., Haselton J.R., and Sun M.K. Sympathoexcitatory neurons of the rostroventrolateral medulla and the origin of the sympathetic vasomotor tone. Prog. Brain Res. 81 (1989) 105-116
20. Hayar A., and Guyenet P.G. Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL. J. Neurophysiol. 83 (2000) 766-776
21. Haxhiu M.A., Dreshaj I., Schafer S.G., and Ernsberger P. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 24 (1994) 1-8
22. Haywood J.R., Shaffer R.A., Fastenow C., Fink G.D., and Brody M.J. Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat. Am. J. Physiol. 241 (1981) H273-H278
23. Head G.A., and Burke S.L. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit. J. Hypertens. 16 (1998) 503-517
24. Kennedy W.B., Crane L., Gonzalez R.R., George O.K., and Edwards L.P. Centrally acting imidazolines stimulate vascular alpha 1A-adrenergic receptors in rat-tail artery. Cell. Mol. Neurobiol. 26 (2006) 643-655
25. Mayorov D., Chernobelski M., and Medvedev O. Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. J. Cardiovasc. Pharmacol. 22 (1993) 314-320
26. Menani J.V., Sato M.A., Haikel L., Vieira A.A., de Andrade C.A., da Silva D.C., Renzi A., and De Luca Jr. L.A. Central moxonidine on water and NaCl intake. Brain Res. Bull. 49 (1999) 273-279
27. 2-adrenergic/imidazoline receptors in the control of thirst, sodium appetite and renal excretion. In: Chen F.J. (Ed). New Trends in Brain Research (2006), Nova Science Publishers, New York 95-126
28. Moreira T.S., Takakura A.C., Colombari E., De Luca Jr. L.A., Renzi A., and Menani J.V. Central moxonidine on salivary gland blood flow and cardiovascular responses to pilocarpine. Brain Res. 987 (2003) 155-163
29. Moreira T.S., Takakura A.C., Menani J.V., Sato M.A., and Colombari E. Central blockade of nitric oxide synthesis reduces moxonidine-induced hypotension. Br. J. Pharmacol. 142 (2004) 765-771
30. Moreira T.S., Takakura A.C., Sato M.A., Menani J.V., and Colombari E. Antihypertensive responses elicited by central moxonidine in rats: possible role of nitric oxide. J. Cardiovasc. Pharmacol. 47 (2006) 780-787
31. Nurminen M.L., Culman J., Haass M., Chung O., and Unger T. Effect of moxonidine on blood pressure and sympathetic tone in spontaneously hypertensive rats. Eur. J. Pharmacol. 362 (1998) 61-67
32. Penner S.B., and Smyth D.D. Sodium excretion following central administration of an I1 imidazoline receptor agonist, moxonidine. Br. J. Pharmacol. 112 (1994) 1089-1094
33. Raasch W., Chun K.R.J., Dendorfer A., and Dominiak P. Positive inotropic effects of imidazoline derivatives are not mediated via imidazoline binding sites but alpha1-adrenergic receptors. Jpn. J. Pharmacol. 84 (2000) 1-6
34. Schlicker E., Armah B.I., and Gothert M. Central presynaptic alpha 2-autoreceptors are involved in the blood pressure-lowering effect of moxonidine. J. Cardiovasc. Pharmacol. 16 (1990) 15-22
35. Smyth D.D., and Penner S.B. Imidazoline receptor mediated natriuresis: central and/or peripheral effect?. J. Auton. Nerv. Syst. 72 (1998) 155-162
36. Smyth D.D., and Penner S.B. Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Ann. N.Y. Acad. Sci. 881 (1999) 344-357
37. Sy G.Y., Bruban V., and Bousquet P. Nitric oxide discriminates the sites and mechanisms of action of centrally acting anti-hypertensive drugs in rabbits. Neuropharmacology 43 (2002) 1330-1338
38. Tibirica E., Feldman J., and Bousquet P. Differences in the ability of yohimbine to antagonize the hypotensive effect of clonidine in normotensive and spontaneously hypertensive anesthetized rats. J. Pharmacol. Exp. Ther. 244 (1988) 1062-1066
39. Tolentino-Silva F.P., Haxhiu M.A., Waldbaum S., Dreshaj I., and Ernsberger P. Alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice. Brain Res. 862 (2000) 26-35
40. Urban R., Szabo B., and Starke K. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur. J. Pharmacol. 282 (1995) 19-28